Abstract 180P
Background
Circadian rhythms (CRs) are crucial biological processes that influence various physiological functions in humans. Previous studies from our team have shown that chronic circadian disruption, specifically chronic jetlag (CJL), increases tumor burden in a mouse melanoma model. The tumor immune microenvironment plays a complex regulatory role in tumorigenesis. However, the specific immune cell functions regulated by circadian disruption to promote tumor progression remain largely undefined. This study aims to demonstrate the critical role of NK cells in the innate immune system during circadian disruption across various mouse models.
Methods
We utilized three distinct mouse models representing varying immune states: C57BL/6 mice, NOD-SCID mice (lacking T/B cells), and B-NDG mice (lacking T/B/NK cells), melanomas were inoculated subcutaneously. Light was manipulated to modulate the circadian clock. Mice were maintained under normal light-dark environment (LD) or CJL environment (6-hour advance of the LD12:12 cycle every 2 days). We use RNA-seq, flow cytometry and quantitative immunofluorescence to analysis tumor immune microenvironment.
Results
Our findings indicate that tumor growth rates significantly increased under CJL in C57 and NOD-SCID mice compared to normal light-dark schedules. In contrast, the tumor growth rate difference between the two rhythm patterns disappeared in NK-cell-deficient B-NDG mice. Flow cytometry analysis revealed that in C57 mice, CJL led to an increase in CD8+ T cells and a decrease in NK cells in tumors, with similar trends observed in the spleen. Additionally, RNA-seq data indicated that CJL inhibits pathways related to both innate and adaptive immunity in tumors, significantly downregulating NK cell function pathways.
Conclusions
These data demonstrate that chronic circadian disruption promotes tumor progression by altering the tumor immune microenvironment, with changes in NK cell quantity and function playing a pivotal role in CJL's effects on tumor growth.
Legal entity responsible for the study
West China Hospital, Sichuan University.
Funding
Sichuan Science and Technology Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session